Aspirin Improves Nonalcoholic Fatty Liver Disease and Atherosclerosis Through Regulation of the PPARδ-AMPK-PGC-1α Pathway in Dyslipidemic Conditions

BioMed Research International - United States
doi 10.1155/2020/7806860
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Hindawi Limited

Related search

Treatment of Nonalcoholic Fatty Liver Disease: Role of AMPK

American Journal of Physiology - Endocrinology and Metabolism
EndocrinologyPhysiologyMetabolismDiabetes
2016English

Berberine Improves Glucogenesis and Lipid Metabolism in Nonalcoholic Fatty Liver Disease

BMC Endocrine Disorders
MedicineEndocrinologyMetabolismDiabetes
2017English

Nonalcoholic Fatty Liver Disease

Hypertension
Internal Medicine
2020English

The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis

Journal of Clinical and Experimental Hepatology
Hepatology
2015English

Nonalcoholic Fatty Liver Disease

Gastroenterology
HepatologyGastroenterology
2002English

Nonalcoholic Fatty Liver Disease in Psoriasis

British Journal of Dermatology
DermatologyMedicine
2018English

Nonalcoholic Fatty Liver Disease in 2020

Gastroenterology
HepatologyGastroenterology
2020English

Ethnicity and Nonalcoholic Fatty Liver Disease

Hepatology
MedicineHepatology
2012English

In Brief: Nonalcoholic Fatty Liver Disease

Pediatrics in Review
MedicineChild HealthPediatricsPerinatology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy